TD Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17.8M Sell
204,628
-20,706
-9% -$2.15M 0.02% 527
2026
Q2
$22M Buy
225,334
+108,758
+93% +$9.5M 0.02% 490
2026
Q1
$9.8M Buy
116,576
+84,826
+267% +$4.91M 0.01% 650
2025
Q4
$1.31M Buy
31,750
+4,092
+15% +$159K ﹤0.01% 1068
2025
Q3
$1.09M Buy
+27,658
New +$707K ﹤0.01% 1073

Other funds holding DNTH

TD Asset Management's DNTH Position: Q3 2026 in Review

TD Asset Management reduced its Dianthus Therapeutics (DNTH) stake by 9.2% in Q3 2026, selling an estimated $2.15M and leaving 204,628 shares worth $17.8M. The position accounts for 0.02% of the portfolio, ranked #527.

TD Asset Management first reported a position in DNTH in Q3 2025 and has held it in 5 quarters since. The position peaked at $22M in Q2 2026. 275 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • TD Asset Management held 204,628 shares of Dianthus Therapeutics worth $17.8M as of Q3 2026.
  • TD Asset Management sold 20,706 Dianthus Therapeutics shares in Q3 2026, an estimated $2.15M.
  • Dianthus Therapeutics made up 0.02% of TD Asset Management's portfolio in Q3 2026, its #527 holding.
  • TD Asset Management first reported a position in Dianthus Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • TD Asset Management's Dianthus Therapeutics position peaked at $22M in Q2 2026.
  • 275 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on TD Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.